Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.

Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ.

Neuro Oncol. 2017 Jan;19(1):i1-i24. doi: 10.1093/neuonc/now197. Review.

PMID:
28031389
2.

Topotecan Delivery to the Optic Nerve after Ophthalmic Artery Chemosurgery.

Taich P, Requejo F, Asprea M, Sgroi M, Gobin P, Abramson DH, Chantada G, Schaiquevich P.

PLoS One. 2016 Mar 9;11(3):e0151343. doi: 10.1371/journal.pone.0151343. eCollection 2016.

3.

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.

Galetti M, Petronini PG, Fumarola C, Cretella D, La Monica S, Bonelli M, Cavazzoni A, Saccani F, Caffarra C, Andreoli R, Mutti A, Tiseo M, Ardizzoni A, Alfieri RR.

PLoS One. 2015 Nov 4;10(11):e0141795. doi: 10.1371/journal.pone.0141795. eCollection 2015.

4.

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer.

Zou ZZ, Nie PP, Li YW, Hou BX, Rui-Li, Shi XP, Ma ZK, Han BW, Luo XY.

Oncotarget. 2017 Apr 4;8(14):22414-22432. doi: 10.18632/oncotarget.5628.

5.

Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes.

Dai C, Ma S, Wang F, Zhao H, Wu X, Huang Z, Chen Z, To K, Fu L.

Oncotarget. 2015 Jul 10;6(19):17738-52.

6.

Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.

Qiu JG, Zhang YJ, Li Y, Zhao JM, Zhang WJ, Jiang QW, Mei XL, Xue YQ, Qin WM, Yang Y, Zheng DW, Chen Y, Wei MN, Shi Z.

Oncotarget. 2015 Jun 20;6(17):15494-509.

7.

β-adrenergic receptor-dependent alterations in murine cardiac transcript expression are differentially regulated by gefitinib in vivo.

Talarico JA, Carter RL, Grisanti LA, Yu JE, Repas AA, Tilley DG.

PLoS One. 2014 Jun 5;9(6):e99195. doi: 10.1371/journal.pone.0099195. eCollection 2014.

8.

Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.

Noguchi K, Katayama K, Sugimoto Y.

Pharmgenomics Pers Med. 2014 Feb 5;7:53-64. doi: 10.2147/PGPM.S38295. eCollection 2014. Review.

9.

Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.

Ma L, Zhang G, Miao XB, Deng XB, Wu Y, Liu Y, Jin ZR, Li XQ, Liu QZ, Sun DX, Testa JR, Yao KT, Xiao GH.

FEBS J. 2013 May;280(9):2027-41. doi: 10.1111/febs.12226. Epub 2013 Apr 8.

10.

Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.

Agarwal S, Mittapalli RK, Zellmer DM, Gallardo JL, Donelson R, Seiler C, Decker SA, Santacruz KS, Pokorny JL, Sarkaria JN, Elmquist WF, Ohlfest JR.

Mol Cancer Ther. 2012 Oct;11(10):2183-92. doi: 10.1158/1535-7163.MCT-12-0552. Epub 2012 Aug 13.

11.

Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.

Wang F, Mi YJ, Chen XG, Wu XP, Liu Z, Chen SP, Liang YJ, Cheng C, To KK, Fu LW.

Mol Med. 2012 Jul 18;18:887-98. doi: 10.2119/molmed.2011.00444.

12.

Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Natarajan K, Xie Y, Baer MR, Ross DD.

Biochem Pharmacol. 2012 Apr 15;83(8):1084-103. doi: 10.1016/j.bcp.2012.01.002. Epub 2012 Jan 11. Review.

13.

Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.

Mandery K, Glaeser H, Fromm MF.

Br J Pharmacol. 2012 Jan;165(2):345-62. doi: 10.1111/j.1476-5381.2011.01618.x. Review.

14.

Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.

Agarwal S, Hartz AM, Elmquist WF, Bauer B.

Curr Pharm Des. 2011;17(26):2793-802. Review.

15.

Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters.

Shukla S, Skoumbourdis AP, Walsh MJ, Hartz AM, Fung KL, Wu CP, Gottesman MM, Bauer B, Thomas CJ, Ambudkar SV.

Mol Pharm. 2011 Aug 1;8(4):1292-302. doi: 10.1021/mp2001022. Epub 2011 Jun 16.

16.

MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.

Zhang F, Throm SL, Murley LL, Miller LA, Steven Zatechka D Jr, Kiplin Guy R, Kennedy R, Stewart CF.

Biochem Pharmacol. 2011 Jul 1;82(1):24-34. doi: 10.1016/j.bcp.2011.03.024. Epub 2011 Apr 1.

17.

HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.

Fukuoka H, Cooper O, Mizutani J, Tong Y, Ren SG, Bannykh S, Melmed S.

Mol Endocrinol. 2011 Jan;25(1):92-103. doi: 10.1210/me.2010-0353. Epub 2010 Nov 24.

18.

Improving cancer chemotherapy with modulators of ABC drug transporters.

Shukla S, Ohnuma S, Ambudkar SV.

Curr Drug Targets. 2011 May;12(5):621-30. Review.

19.

Metabolism considerations for kinase inhibitors in cancer treatment.

Duckett DR, Cameron MD.

Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1175-93. doi: 10.1517/17425255.2010.506873. Review.

20.

Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.

Carcaboso AM, Elmeliegy MA, Shen J, Juel SJ, Zhang ZM, Calabrese C, Tracey L, Waters CM, Stewart CF.

Cancer Res. 2010 Jun 1;70(11):4499-508. doi: 10.1158/0008-5472.CAN-09-4264. Epub 2010 May 11.

Supplemental Content

Support Center